An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's significantly reduce disease burden in two phase 3 trials.
In the TEMPO-3 trial, topline findings reported earlier this year showed that patients with PD and motor fluctuations receiving once-daily tavapadon as adjunct therapy toenrolled 507 patients aged 40-80 years with PD who had a modified Hoehn and Yahr score of 2, 2.5, or 3 during"on" periods, a good response to levodopa on a minimum stable dose of at least 400 mg/d, and a minimum of 2.5 hours of"off" time on 2 consecutive days during screening.
Patients receiving once-daily adjunctive tavapadon had a significant 1.1-hour increase in the primary outcome of total daily"on" time without troublesome dyskinesias compared with placebo at 27 weeks, based on the two-day average of the self-reported Hauser diary . Modest decreases in supine blood pressure and weight were observed in patients treated with tavapadon, he said.
What distinguishes tavapadon is its tolerability and unique dopamine receptor profile. This profile places tavapadon slightly closer to levodopa than other dopamine agonists in that it has little effect on the D3 receptor, which has been linked to impulse control behavioral disorders, she said. TEMPO-1 is being conducted at 77 sites in the US, Europe, Australia, Israel, and Ukraine in 522 participants who were treatment naive or had received dopaminergic agents for less than 3 months and not within 2 months of baseline.
Parkinson Disease Parkinsons Parkinson Parkinson Disease (PD) Dopamine Dopamine Agonist Receptors Dyskinesia L-Dopa Levodopa Orthostatic Hypotension Blood Hypotension Malignant Pancreatic Neoplasm Pancreatic Cancer Cancer Of The Pancreas Depression Headache Healthcare And Medical Technology Health And Medical Tech Health And Med Tech Health And Medical Technology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Phase 3 Izokibep Study in Hidradenitis Suppurativa Produces Promising ResultsThe investigational IL-17A inhibitor izokibep was found to induce clear clinical responses in people with moderate to severe HS within a few weeks of treatment.
Read more »
Coal Phase-Out Could Create Help ‘Positive Tipping Point’, Study FindsJamie Hailstone is a UK-based reporter, who covers sustainability, focussing on pollution, the circular economy and calls for healthier cities. He’s covered electric school buses, air quality and plastic pollution in the oceans. Previously, Hailstone was editor of Environment Journal Online and Air Quality News.
Read more »
Mytheresa reports positive FY24 results, reaches double-digit growth in H2“Money-can't-buy” experiences for top customers and luxury brand partnerships are boosting the online luxury retailer’s books as it nears a billion dollars in annual sales.
Read more »
Pfizer Says Experimental Drug for Deadly Cancer Condition Shows Positive Trial ResultsPfizer announced positive mid-stage trial results for its experimental drug, ponsegromab, targeting cancer cachexia. Patients taking the treatment experienced improvements in body weight, muscle mass, quality of life, and physical function.
Read more »
Kamala Harris Has Biggest Favorability Jump Since George W. Bush After 9/11The results come as a part of a very positive poll from NBC News on Sunday.
Read more »
TEMPO Trials: Tavapadon Marches on in Parkinson's DiseaseThe experimental oral partial dopamine receptor agonist racked up positive results without a new safety signal in two phase 3 trials.
Read more »